226 related articles for article (PubMed ID: 17090547)
21. IFI16 is an essential mediator of growth inhibition, but not differentiation, induced by the leukemia inhibitory factor/JAK/STAT pathway in medullary thyroid carcinoma cells.
Kim EJ; Park JI; Nelkin BD
J Biol Chem; 2005 Feb; 280(6):4913-20. PubMed ID: 15572361
[TBL] [Abstract][Full Text] [Related]
22. Notch signaling induces cell cycle arrest in small cell lung cancer cells.
Sriuranpong V; Borges MW; Ravi RK; Arnold DR; Nelkin BD; Baylin SB; Ball DW
Cancer Res; 2001 Apr; 61(7):3200-5. PubMed ID: 11306509
[TBL] [Abstract][Full Text] [Related]
23. Valproic acid activates notch-1 signaling and regulates the neuroendocrine phenotype in carcinoid cancer cells.
Greenblatt DY; Vaccaro AM; Jaskula-Sztul R; Ning L; Haymart M; Kunnimalaiyaan M; Chen H
Oncologist; 2007 Aug; 12(8):942-51. PubMed ID: 17766653
[TBL] [Abstract][Full Text] [Related]
24. Mortalin (GRP75/HSPA9) upregulation promotes survival and proliferation of medullary thyroid carcinoma cells.
Starenki D; Hong SK; Lloyd RV; Park JI
Oncogene; 2015 Aug; 34(35):4624-34. PubMed ID: 25435367
[TBL] [Abstract][Full Text] [Related]
25. EGFR mediates activation of RET in lung adenocarcinoma with neuroendocrine differentiation characterized by ASCL1 expression.
Bhinge K; Yang L; Terra S; Nasir A; Muppa P; Aubry MC; Yi J; Janaki N; Kovtun IV; Murphy SJ; Halling G; Rahi H; Mansfield A; de Andrade M; Yang P; Vasmatzis G; Peikert T; Kosari F
Oncotarget; 2017 Apr; 8(16):27155-27165. PubMed ID: 28460442
[TBL] [Abstract][Full Text] [Related]
26. Notch1 signaling inhibits growth of human hepatocellular carcinoma through induction of cell cycle arrest and apoptosis.
Qi R; An H; Yu Y; Zhang M; Liu S; Xu H; Guo Z; Cheng T; Cao X
Cancer Res; 2003 Dec; 63(23):8323-9. PubMed ID: 14678992
[TBL] [Abstract][Full Text] [Related]
27. Growth suppression induced by Notch1 activation involves Wnt-beta-catenin down-regulation in human tongue carcinoma cells.
Duan L; Yao J; Wu X; Fan M
Biol Cell; 2006 Aug; 98(8):479-90. PubMed ID: 16608439
[TBL] [Abstract][Full Text] [Related]
28. RET Kinase-Regulated MicroRNA-153-3p Improves Therapeutic Efficacy in Medullary Thyroid Carcinoma.
Joo LJS; Weiss J; Gill AJ; Clifton-Bligh R; Brahmbhatt H; MacDiarmid JA; Gild ML; Robinson BG; Zhao JT; Sidhu SB
Thyroid; 2019 Jun; 29(6):830-844. PubMed ID: 30929576
[No Abstract] [Full Text] [Related]
29. Notch in the development of thyroid C-cells and the treatment of medullary thyroid cancer.
Cook M; Yu XM; Chen H
Am J Transl Res; 2010 Feb; 2(1):119-25. PubMed ID: 20182588
[TBL] [Abstract][Full Text] [Related]
30. Upregulation of ASCL1 and inhibition of Notch signaling pathway characterize progressive astrocytoma.
Somasundaram K; Reddy SP; Vinnakota K; Britto R; Subbarayan M; Nambiar S; Hebbar A; Samuel C; Shetty M; Sreepathi HK; Santosh V; Hegde AS; Hegde S; Kondaiah P; Rao MR
Oncogene; 2005 Oct; 24(47):7073-83. PubMed ID: 16103883
[TBL] [Abstract][Full Text] [Related]
31. Regulation of neuroendocrine differentiation in gastrointestinal carcinoid tumor cells by notch signaling.
Nakakura EK; Sriuranpong VR; Kunnimalaiyaan M; Hsiao EC; Schuebel KE; Borges MW; Jin N; Collins BJ; Nelkin BD; Chen H; Ball DW
J Clin Endocrinol Metab; 2005 Jul; 90(7):4350-6. PubMed ID: 15870121
[TBL] [Abstract][Full Text] [Related]
32. Inactivation of glycogen synthase kinase-3beta, a downstream target of the raf-1 pathway, is associated with growth suppression in medullary thyroid cancer cells.
Kunnimalaiyaan M; Vaccaro AM; Ndiaye MA; Chen H
Mol Cancer Ther; 2007 Mar; 6(3):1151-8. PubMed ID: 17363508
[TBL] [Abstract][Full Text] [Related]
33. The cholecystokinin2-receptor mediates calcitonin secretion, gene expression, and proliferation in the human medullary thyroid carcinoma cell line, TT.
Bläker M; Arrenberg P; Stange I; Schulz M; Burghardt S; Michaelis H; Pace A; Greten H; von Schrenck T; de Weerth A
Regul Pept; 2004 Apr; 118(1-2):111-7. PubMed ID: 14759564
[TBL] [Abstract][Full Text] [Related]
34. The HIV protease inhibitor nelfinavir down-regulates RET signaling and induces apoptosis in medullary thyroid cancer cells.
Kushchayeva Y; Jensen K; Recupero A; Costello J; Patel A; Klubo-Gwiezdzinska J; Boyle L; Burman K; Vasko V
J Clin Endocrinol Metab; 2014 May; 99(5):E734-45. PubMed ID: 24483157
[TBL] [Abstract][Full Text] [Related]
35. MK-2206 causes growth suppression and reduces neuroendocrine tumor marker production in medullary thyroid cancer through Akt inhibition.
Burke JF; Schlosser L; Harrison AD; Kunnimalaiyaan M; Chen H
Ann Surg Oncol; 2013 Nov; 20(12):3862-8. PubMed ID: 23900743
[TBL] [Abstract][Full Text] [Related]
36. POU domain transcription factor BRN2 is crucial for expression of ASCL1, ND1 and neuroendocrine marker molecules and cell growth in small cell lung cancer.
Ishii J; Sato H; Sakaeda M; Shishido-Hara Y; Hiramatsu C; Kamma H; Shimoyamada H; Fujiwara M; Endo T; Aoki I; Yazawa T
Pathol Int; 2013 Mar; 63(3):158-68. PubMed ID: 23530560
[TBL] [Abstract][Full Text] [Related]
37. Indomethacin inhibits cell growth of medullary thyroid carcinoma by reducing cell cycle progression into S phase.
Tomoda C; Moatamed F; Naeim F; Hershman JM; Sugawara M
Exp Biol Med (Maywood); 2008 Nov; 233(11):1433-40. PubMed ID: 18791128
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of growth in medullary thyroid cancer cells with histone deacetylase inhibitors and lithium chloride.
Adler JT; Hottinger DG; Kunnimalaiyaan M; Chen H
J Surg Res; 2010 Apr; 159(2):640-4. PubMed ID: 19394967
[TBL] [Abstract][Full Text] [Related]
39. Cofilin is a mediator of RET-promoted medullary thyroid carcinoma cell migration, invasion and proliferation.
Giardino E; Catalano R; Barbieri AM; Treppiedi D; Mangili F; Spada A; Arosio M; Mantovani G; Peverelli E
Mol Cell Endocrinol; 2019 Sep; 495():110519. PubMed ID: 31352037
[TBL] [Abstract][Full Text] [Related]
40. Aurora kinases are expressed in medullary thyroid carcinoma (MTC) and their inhibition suppresses in vitro growth and tumorigenicity of the MTC derived cell line TT.
Baldini E; Arlot-Bonnemains Y; Sorrenti S; Mian C; Pelizzo MR; De Antoni E; Palermo S; Morrone S; Barollo S; Nesca A; Moretti CG; D'Armiento M; Ulisse S
BMC Cancer; 2011 Sep; 11():411. PubMed ID: 21943074
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]